- Home
- LUCD vs ACHV Comparison
LUCD vs ACHV Comparison
Compare LUCD & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCD
- ACHV
- Stock Information
- Founded
- LUCD 2018
- ACHV N/A
- Country
- LUCD United States
- ACHV United States
- Employees
- LUCD N/A
- ACHV N/A
- Industry
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- LUCD Health Care
- ACHV Health Care
- Exchange
- LUCD Nasdaq
- ACHV Nasdaq
- Market Cap
- LUCD 112.5M
- ACHV 131.2M
- IPO Year
- LUCD 2021
- ACHV N/A
- Fundamental
- Price
- LUCD $1.11
- ACHV $2.68
- Analyst Decision
- LUCD Strong Buy
- ACHV Strong Buy
- Analyst Count
- LUCD 4
- ACHV 3
- Target Price
- LUCD $3.94
- ACHV $14.33
- AVG Volume (30 Days)
- LUCD 1.5M
- ACHV 2.0M
- Earning Date
- LUCD 08-11-2025
- ACHV 08-07-2025
- Dividend Yield
- LUCD N/A
- ACHV N/A
- EPS Growth
- LUCD N/A
- ACHV N/A
- EPS
- LUCD N/A
- ACHV N/A
- Revenue
- LUCD $4,173,000.00
- ACHV N/A
- Revenue This Year
- LUCD $49.70
- ACHV N/A
- Revenue Next Year
- LUCD $198.20
- ACHV N/A
- P/E Ratio
- LUCD N/A
- ACHV N/A
- Revenue Growth
- LUCD 39.89
- ACHV N/A
- 52 Week Low
- LUCD $0.72
- ACHV $1.84
- 52 Week High
- LUCD $1.80
- ACHV $5.31
- Technical
- Relative Strength Index (RSI)
- LUCD 44.54
- ACHV 48.14
- Support Level
- LUCD $1.08
- ACHV $2.58
- Resistance Level
- LUCD $1.14
- ACHV $2.77
- Average True Range (ATR)
- LUCD 0.07
- ACHV 0.18
- MACD
- LUCD 0.00
- ACHV 0.05
- Stochastic Oscillator
- LUCD 41.03
- ACHV 78.48
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.